Safety and Efficacy of NK520 to Treat Pediatric Relapsed/Refractory Acute Myeloid Leukemia

This trial is testing a new cell therapy called NK520 — made from natural killer (NK) immune cells — for children and teenagers with relapsed or refractory acute myeloid leukemia (AML), a type of blood cancer that starts in the bone marrow. NK520 aims to use the body's own immune system to destroy leukemia cells. **You may be eligible if...** - You are between 6 and 18 years old with a confirmed diagnosis of AML - Your leukemia has relapsed (come back after remission) or is refractory (not responding to at least 2 prior treatment regimens) - You are not eligible for other currently available treatments **You may NOT be eligible if...** - You are younger than 6 or older than 18 - Your leukemia does not meet the WHO criteria for AML - You have certain other serious health conditions - Your organ function does not meet minimum safety thresholds Talk to your doctor to see if this trial is right for you.